lundi 16 novembre 2026
RechercherExplore
Via News Knowledge File

AstraZeneca AB

organization80% conf.·synced Aug 13, 2026

Pharmaceutical company with license agreement with Insmed

57
sourced metrics
409
relationships
20
stated objectives
1
Via News reports
Working data, not the finished story. This is what our AI has read and extracted from source documents so far. Before anything here becomes news, it is checked against the original source, fact-checked and put in context. Figures can be incomplete or wrongly labelled at this stage; our articles are the end product. How we source

Key metrics · each point sourced

Dividend Per Share
$1.06
Jul 27, 2026source
Revenue
$30.59B
Jul 27, 2026source
Eps
$1.61
Jul 27, 2026source
Stock Price
$168.9
Jul 17, 2026source
Stock Return Ytd
12.1%
Apr 1, 2026source
Stock Return 7day
-0.6%
Apr 1, 2026source
Intrinsic Value Dcf
$238.68
Apr 1, 2026source
Valuation Score
3out of 6
Apr 1, 2026source
Free Cash Flow
$9.49B
Apr 1, 2026source
Projected Free Cash Flow
$20.16B
Apr 1, 2026source
Stock Return 30day
5.2%
Apr 1, 2026source
Stock Return 1year
54.8%
Apr 1, 2026source
Marathon Holding Value
$12.8M
Mar 31, 2026source
Marathon Holding Pct Aum
2.9%
Mar 31, 2026source
Analyst Price Target
£165.33B
Mar 1, 2026source
Return 1year
21.8%
Mar 1, 2026source
Free Cash Flow Projected
$20.2B
Mar 1, 2026source
Intrinsic Value Per Share
£242.86B
Mar 1, 2026source

Stated objectives

Eliminate cancer as a cause of death

source
stated

Transform the lives of patients living with malignant, rare and other related hematologic diseases through innovative medicines

source
stated

Reach $80bn in annual sales by 2030

source
target: 80 billion USD by 2030-01-01 00:00:00stated

Achieve operating margin in mid-thirties percent range

source
target: 35 percent stated

High single digit revenue growth for 2025 on constant currency basis

source
target: 7-9 percent by 2025-01-01 00:00:00stated

Low double digit growth in adjusted earnings per share for 2025 on constant currency basis

source
target: 10-12 percent by 2025-01-01 00:00:00stated

Increase total revenue by mid-to-high single-digit percentage for FY 2026 at constant exchange rates

source
target: mid-to-high single-digit percentage growth by 2026-12-31 00:00:00stated

Increase core EPS by low double-digit percentage for FY 2026 at constant exchange rates

source
target: low double-digit percentage growth by 2026-12-31 00:00:00stated

Invest $15 billion in China through 2030 to expand medicines manufacturing and R&D

source
target: $15 billion by 2030-12-31 00:00:00stated

Complete more than 20 Phase 3 trial readouts in 2026

source
target: 20+ Phase 3 readouts by 2026-12-31 00:00:00stated

Relationship graph · 409 connections

Developed by
145
Competes with
73
Employs
25
Partnered with
21
Located in
13
Headquartered in
12
contracted by
10
Acquired by
10

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →